Diaceutics PLC PDMR Shareholding/Share Incentive Plan (4196N)
31 May 2022 - 9:12PM
UK Regulatory
TIDMDXRX
RNS Number : 4196N
Diaceutics PLC
31 May 2022
31 May 2022
Diaceutics PLC
("Diaceutics" or "the Company")
PDMR Shareholding/Share Incentive Plan
Diaceutics PLC , ( AIM: DXRX), the diagnostic commercialisation
company has been notified that on 27 May 2022, Yorkshire Building
Society and Zedra Trust Company (Guernsey) Limited, the trustees of
the Global Diaceutics plc 2020 Employee Benefit Trust , have
purchased ordinary shares ("Shares") on behalf of Stefan McDonald
and Susanne Munksted (PDMRs), in respect of their purchase of
Shares pursuant to the Company's UK and Global Share Incentive Plan
("the SIP Schemes") for employees . These purchases will be made
each month until further notice.
In accordance with the SIP Schemes, the Company has matched
these purchases with a matched share award over an equivalent
number of Shares purchased by the employee, in the proportion of
1:1.
Enquiries:
Diaceutics PLC
Nick Roberts, Chief Financial Officer Via Alma PR
Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710
7600
Ben Maddison
Stewart Wallace
Nick Adams
Alma PR Tel: +44(0)20 3405
0205
Caroline Forde diaceutics@almapr.co.uk
Kieran Breheny
Matthew Young
About Diaceutics
At Diaceutics we believe that every patient should have access
to the right treatment at the right time. We provide the world's
leading pharmaceutical companies with an end-to-end solution for
the launch of precision medicine diagnostics enabled by DXRX - The
Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform
for precision medicine, integrating multiple pipelines of
real-world diagnostic testing data from a global network of
laboratories.
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
---- -----------------------------------------------------------------------------------
a. Name Stefan McDonald
------------------------------------------------------
2 Reason for notification
--------------------------- ------------------------------------------------------
a. Position/Status Chief Growth Officer and PDMR
--------------------------- ------------------------------------------------------
b. Initial notification/ Initial
Amendment
------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
---------------------------
b. LEI 213800VEWQBB39ZB8J81
--------------------------- ------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---- -----------------------------------------------------------------------------------
a. Description of Ordinary shares of GBP 0.002 each
the financial
instrument, type ISIN: GB00BJQTGV64
of instrument
Identification
Code
--------------------------- ------------------------------------------------------
b. Nature of the Ongoing non-discretionary purchase of Shares
transaction matched by the grant of conditional share
award over Shares under the Diaceutics plc
UK Share Incentive Plan ("SIP")
--------------------------- ------------------------------------------------------
c. Price(s) and volume(s) Share purchase:
--------------------------- ----------------------------- --- ----------
Price(s) Volume(s)
--------------------------- ------------
111.90 p 134
------------ ----------------
Matched share award:
------------------------------
Price(s) Volume(s)
------------
111.90 p 134
------------ ----------------
e. Date of the transaction Share purchase and Matched Share award:
27 May 2022
--------------------------- ------------------------------------------------------
f. Place of the transaction Share Purchase and Matched Share Award:
AIM Market of the London Stock Exchange
--------------------------- ------------------------------------------------------
Notification of a Transaction pursuant to Article 19(1) of Regulation
(EU) No. 596/2014
1 Details of the person discharging managerial responsibilities/person
closely associated
---- -----------------------------------------------------------------------------------
a. Name Susanne Munksted
------------------------------------------------------
2 Reason for notification
--------------------------- ------------------------------------------------------
a. Position/Status Chief Precision Medicine Officer and PDMR
--------------------------- ------------------------------------------------------
b. Initial notification/ Initial
Amendment
------------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
a. Name Diaceutics PLC
---------------------------
b. LEI 213800VEWQBB39ZB8J81
--------------------------- ------------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
---- -----------------------------------------------------------------------------------
a. Description of Ordinary shares of GBP 0.002 each
the financial
instrument, type ISIN: GB00BJQTGV64
of instrument
Identification
Code
--------------------------- ------------------------------------------------------
b. Nature of the Ongoing non-discretionary purchase of Shares
transaction matched by the grant of conditional share
award over Shares under the Global Share
Incentive Plan ("SIP")
--------------------------- ------------------------------------------------------
c. Price(s) and volume(s) Share purchase:
--------------------------- ----------------------------- --- ----------
Price(s) Volume(s)
--------------------------- ------------
112.00 p 131
------------ ----------------
Conditional share award:
------------------------------
Price(s) Volume(s)
------------
Nil 131
------------ ----------------
e. Date of the transaction Share purchase and Conditional share award:
27 May 2022
--------------------------- ------------------------------------------------------
f. Place of the transaction Share Purchase: AIM Market of the London
Stock Exchange
Conditional share award: Off-Market
--------------------------- ------------------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBKDBKDBKDCPN
(END) Dow Jones Newswires
May 31, 2022 07:12 ET (11:12 GMT)
Diaceutics (LSE:DXRX)
Historical Stock Chart
From Apr 2024 to May 2024
Diaceutics (LSE:DXRX)
Historical Stock Chart
From May 2023 to May 2024